Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H7Cl2N5 |
Molecular Weight | 256.0916 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
c1cc(c(c(c1)Cl)Cl)-c2c(N)[nH]c(=N)nn2
InChI
InChIKey=PYZRQGJRPPTADH-UHFFFAOYSA-N
InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)
Molecular Formula | C9H7Cl2N5 |
Molecular Weight | 256.0916 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Lamotrigine (marketed as Lamictal) is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder. The precise mechanism(s) by which lamotrigine exerts its anticonvulsant action are unknown. In animal models designed to detect anticonvulsant activity, lamotrigine was effective in preventing seizure spread in the maximum electroshock (MES) and pentylenetetrazol (scMet) tests, and prevented seizures in the visually and electrically evoked after-discharge (EEAD) tests for antiepileptic activity. Lamotrigine also displayed inhibitory properties in the kindling model in rats both during kindling development and in the fully kindled state. The relevance of these models to human epilepsy, however, is not known. One proposed mechanism of action of lamotrigine, the relevance of which remains to be established in humans, involves an effect on sodium channels. In vitro pharmacological studies suggest that lamotrigine inhibits voltage-sensitive sodium channels, thereby stabilizing neuronal membranes and consequently modulating presynaptic transmitter release of excitatory amino acids (e.g., glutamate and aspartate). Effect of Lamotrigine on N-Methyl d-Aspartate-Receptor Mediated Activity Lamotrigine did not inhibit N-methyl d-aspartate (NMDA)-induced depolarizations in rat cortical slices or NMDA-induced cyclic GMP formation in immature rat cerebellum, nor did lamotrigine displace compounds that are either competitive or noncompetitive ligands at this glutamate receptor complex (CNQX, CGS, TCHP). The IC50 for lamotrigine effects on NMDA-induced currents (in the presence of 3 uM of glycine) in cultured hippocampal neurons exceeded 100 uM. The mechanisms by which lamotrigine exerts its therapeutic action in bipolar disorder have not been established. The mechanisms that underpin the passage of lamotrigine at the blood-brain barrier to its site of action in the brain is poorly understood.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22227272
Curator's Comment:: The mechanisms that underpin the passage of lamotrigine at the blood-brain barrier to its site of action in the brain is poorly understood.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2331043 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | LAMICTAL Approved UseINDICATIONS & USAGE Lamotrigine is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: · partial-onset seizures. · primary generalized tonic-clonic seizures. · generalized seizures of Lennox-Gastaut syndrome. (1.1) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single AED. (1.1) Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. (1.2) Limitations of Use: Treatment of acute manic or mixed episodes is not recommended. Effectiveness of lamotrigine in the acute treatment of mood episodes has not been established. 1.1 Epilepsy Adjunctive Therapy Lamotrigine is indicated as adjunctive therapy for the following seizure types in patients aged 2 years and older: · partial-onset seizures. · primary generalized tonic-clonic (PGTC) seizures. · generalized seizures of Lennox-Gastaut syndrome. Monotherapy Lamotrigine is indicated for conversion to monotherapy in adults (aged 16 years and older) with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED). Safety and effectiveness of lamotrigine have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. 1.2 Bipolar Disorder Lamotrigine is indicated for the maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults in patients treated for acute mood episodes with standard therapy [see Clinical Studies (14.1) Launch Date7.8848642E11 |
|||
Primary | LAMICTAL Approved UseINDICATIONS & USAGE Lamotrigine is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: · partial-onset seizures. · primary generalized tonic-clonic seizures. · generalized seizures of Lennox-Gastaut syndrome. (1.1) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single AED. (1.1) Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. (1.2) Limitations of Use: Treatment of acute manic or mixed episodes is not recommended. Effectiveness of lamotrigine in the acute treatment of mood episodes has not been established. 1.1 Epilepsy Adjunctive Therapy Lamotrigine is indicated as adjunctive therapy for the following seizure types in patients aged 2 years and older: · partial-onset seizures. · primary generalized tonic-clonic (PGTC) seizures. · generalized seizures of Lennox-Gastaut syndrome. Monotherapy Lamotrigine is indicated for conversion to monotherapy in adults (aged 16 years and older) with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED). Safety and effectiveness of lamotrigine have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. 1.2 Bipolar Disorder Lamotrigine is indicated for the maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults in patients treated for acute mood episodes with standard therapy [see Clinical Studies (14.1) Launch Date7.8848642E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4900 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/20047572 |
150 mg 1 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LAMOTRIGINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2518 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00835263 |
200 mg single, oral dose: 200 mg route of administration: oral experiment type: single co-administered: |
LAMOTRIGINE plasma | Homo sapiens population: age: sex: food status: Fed |
|
2912.04 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00834561 |
200 mg single, oral dose: 200 mg route of administration: oral experiment type: single co-administered: |
LAMOTRIGINE plasma | Homo sapiens population: age: sex: food status: Fasted |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
73723 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/20047572 |
150 mg 1 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LAMOTRIGINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
113029.409999999 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00835263 |
200 mg single, oral dose: 200 mg route of administration: oral experiment type: single co-administered: |
LAMOTRIGINE plasma | Homo sapiens population: age: sex: food status: Fed |
|
120080.26 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00834561 |
200 mg single, oral dose: 200 mg route of administration: oral experiment type: single co-administered: |
LAMOTRIGINE plasma | Homo sapiens population: age: sex: food status: Fasted |
|
131594.33 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00835263 |
200 mg single, oral dose: 200 mg route of administration: oral experiment type: single co-administered: |
LAMOTRIGINE plasma | Homo sapiens population: age: sex: food status: Fed |
|
139995.13 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00834561 |
200 mg single, oral dose: 200 mg route of administration: oral experiment type: single co-administered: |
LAMOTRIGINE plasma | Homo sapiens population: age: sex: food status: Fasted |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
22.6 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/20047572 |
150 mg 1 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LAMOTRIGINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
45% |
LAMOTRIGINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >133 uM] | ||||
no | ||||
no | ||||
weak | ||||
weak | ||||
weak | ||||
weak | yes (co-administration study) Comment: Coadministration of Lamotrigine decreased Valproate steady-state concentration by 25%. |
|||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020241s058,020764s051,022251s022lbl.pdf#page=35 Page: 35-36, 52 |
yes [IC50 53.8 uM] | |||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: (PMDA) 31, 39-40, (PMDA_K100) 50 |
major | yes (co-administration study) Comment: Coadministration of Valproic acid (UGT inducer) decreased Lamotrigine CL/F by about 50%. Page: (PMDA) 31, 39-40, (PMDA_K100) 50 |
||
Page: (PMDA) 31, 39-40, (PMDA_K100) 50 |
minor | yes (co-administration study) Comment: Coadministration of Valproic acid (UGT inducer) decreased Lamotrigine CL/F by about 50%. Page: (PMDA) 31, 39-40, (PMDA_K100) 50 |
||
Page: (PMDA) 31, (PMDA_K100) 50-51 |
no [IC50 >100 uM] | |||
Page: (PMDA) 31, (PMDA_K100) 50-51 |
no [IC50 >100 uM] | |||
Page: (PMDA) 31, (PMDA_K100) 50-51 |
no [IC50 >100 uM] | |||
Page: (PMDA) 31, (PMDA_K100) 50-51 |
no [IC50 >100 uM] | |||
Page: (PMDA) 31, (PMDA_K100) 50-51 |
no [IC50 >100 uM] | |||
Page: (PMDA) 31, (PMDA_K100) 50-51 |
no [IC50 >100 uM] | |||
Page: (PMDA) 31, (PMDA_K100) 50-51 |
no [IC50 >100 uM] | |||
Page: (PMDA) 31, (PMDA_K100) 50-51 |
no [IC50 >100 uM] | |||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
Page: (PMDA) 31, (PMDA_K100) 50 |
no | |||
Page: (PMDA) 31, (PMDA_K100) 50 |
no | |||
Page: (PMDA) 31, (PMDA_K100) 50 |
no | |||
Page: (PMDA) 31, (PMDA_K100) 50 |
no | |||
Page: (PMDA) 31, (PMDA_K100) 50 |
no | |||
Page: (PMDA) 31, (PMDA_K100) 50 |
no | |||
Page: (PMDA) 31, (PMDA_K100) 50 |
no | |||
Page: (PMDA) 31, (PMDA_K100) 50 |
no | |||
Page: (PMDA) 31, (PMDA_K100) 50 |
no | |||
Page: (PMDA) 31, (PMDA_K100) 50 |
no | |||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: (PMDA_H100) 34 |
PubMed
Title | Date | PubMed |
---|---|---|
Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications. | 2001 |
|
Bipolar rapid cycling: focus on depression as its hallmark. | 2001 |
|
Introduction: the role of anticonvulsants as mood stabilizers. | 2001 |
|
Cognitive side effects of anticonvulsants. | 2001 |
|
Effects of antiepileptic drugs on cognition. | 2001 |
|
The long-term use of vigabatrin and lamotrigine in patients with severe childhood onset epilepsy. | 2001 |
|
Incompleteness of lamotrigine data. | 2001 |
|
Case reports. | 2001 Apr |
|
Epilepsy and the ovary (cutting out the hysteria). | 2001 Apr |
|
Important changes in the treatment of epilepsy. | 2001 Apr |
|
The combination of lamotrigine and mild hypothermia prevents ischemia-induced increase in hippocampal glutamate. | 2001 Apr |
|
Novel treatments for bipolar disorder. | 2001 Apr |
|
[Sensory neuropathy in HIV infection: pathogenesis and therapy]. | 2001 Apr 14 |
|
Toxicologic causes of giggling. | 2001 Aug |
|
Newer antiepileptic drugs: advantages and disadvantages. | 2001 Aug |
|
Effect of divalproex-lamotrigine combination therapy in frontal lobe seizures. | 2001 Aug |
|
Effect of gabapentin and lamotrigine on mechanical allodynia-like behaviour in a rat model of trigeminal neuropathic pain. | 2001 Aug |
|
Peri-marketing surveillance of lamotrigine in The Netherlands: doctors' and patients' viewpoints. | 2001 Feb |
|
Infantile spasms. | 2001 Feb |
|
Valproate, but not lamotrigine, induces ovarian morphological changes in Wistar rats. | 2001 Feb |
|
Relative bioavailability of lamotrigine chewable dispersible tablets administered rectally. | 2001 Feb |
|
[Lamotrigine in refractory partial and general epilepsies]. | 2001 Jan 1-15 |
|
[Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine]. | 2001 Jan-Feb |
|
The role of new antiepileptic drugs. | 2001 Jul |
|
Antiepileptic drug utilization: a Danish prescription database analysis. | 2001 Jul |
|
Neuroprotective effects of lamotrigine and remacemide on excitotoxicity induced by glutamate agonists in isolated chick retina. | 2001 Jul |
|
Normal growth during lamotrigine monotherapy in pediatric epilepsy patients -- a prospective evaluation of 103 children and adolescents. | 2001 Jul |
|
Lamotrigine in two cases of Rett syndrome. | 2001 Jul |
|
Therapeutic drug monitoring of antiepileptics by capillary electrophoresis. Characterization of assays via analysis of quality control sera containing 14 analytes. | 2001 Jul 27 |
|
Preclinical evaluation of CHF3381 as a novel antiepileptic agent. | 2001 Jun |
|
Single-dose pharmacokinetics of lamotrigine in children: influence of age and antiepileptic comedication. | 2001 Jun |
|
[A casuistic report on Lamotrigine]. | 2001 Jun 20 |
|
[SUNCT syndrome sensitive to lamotrigine]. | 2001 Jun 30 |
|
When treating patients with schizophrenia, what clinical points should be considered if lamotrigine is chosen to augment clozapine? | 2001 Mar |
|
Absence epilepsy with fast rhythmic discharges during sleep: an intermediary form of generalized epilepsy? | 2001 Mar |
|
On the association between valproate and polycystic ovary syndrome. | 2001 Mar |
|
A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy. | 2001 Mar |
|
New generation anti-epileptics for facial pain and headache. | 2001 Mar |
|
Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice. | 2001 Mar |
|
pH-stat strategy and hypothermia of 25 degrees C alone should protect the central nervous system consistently from 75 minutes of circulatory arrest. | 2001 Mar |
|
[Optimal use of lamotrigine in clinical practice: results of an open multicenter trial in refractory epilepsy]. | 2001 May |
|
Influence of cirrhosis on lamotrigine pharmacokinetics. | 2001 May |
|
Modulation of K+-evoked [3H]-noradrenaline release from rat and human brain slices by gabapentin: involvement of KATP channels. | 2001 May |
|
Mechanisms influencing stimulus-response properties of the human corticospinal system. | 2001 May |
|
[Juvenile myoclonic epilepsy]. | 2001 May 16-31 |
|
Lamotrigine analysis in blood and brain by high-performance liquid chromatography. | 2001 May 5 |
|
Differential cognitive and behavioral effects of carbamazepine and lamotrigine. | 2001 May 8 |
|
Pharmacologic management of epilepsy in the elderly. | 2001 May-Jun |
|
Effect of lamotrigine treatment on status epilepticus-induced neuronal damage and memory impairment in rat. | 2001 Sep |
|
Treatment-resistant bipolar disorder. | 2001 Winter |
Patents
Sample Use Guides
Epilepsy—Conversion From Adjunctive Therapy to Monotherapy:
The recommended maintenance dose of LAMICTAL (lamotrigine) as monotherapy is 500 mg/day given in 2 divided doses.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16129425
In vitro, lamotrigine inhibited rat brain A-type of monoamine oxidase (MAO) activities with Ki values (MAO-A, 15 uM; MAO-B, 18 uM) potentially within the therapeutic range for this drug. The effects of lamotrigine on the MAO-A activities of rat brain and human liver preparations were almost identical suggesting minimal species or tissue variation
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:01:18 UTC 2021
by
admin
on
Fri Jun 25 21:01:18 UTC 2021
|
Record UNII |
U3H27498KS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175753
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
||
|
NDF-RT |
N0000175751
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
||
|
FDA ORPHAN DRUG |
91695
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
||
|
WHO-ATC |
N03AX09
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
||
|
WHO-VATC |
QN03AX09
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
||
|
NCI_THESAURUS |
C264
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
||
|
NDF-RT |
N0000008486
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
||
|
LIVERTOX |
539
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3878
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
PRIMARY | |||
|
281-901-8
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
PRIMARY | |||
|
5638
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
PRIMARY | |||
|
2622
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
PRIMARY | |||
|
1540
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
PRIMARY | |||
|
84057-84-1
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
PRIMARY | |||
|
28439
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
PRIMARY | RxNorm | ||
|
7526
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
PRIMARY | |||
|
C38703
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
PRIMARY | |||
|
84057-84-1
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
PRIMARY | |||
|
1356756
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
PRIMARY | USP-RS | ||
|
SUB08393MIG
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
PRIMARY | |||
|
Lamotrigine
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
PRIMARY | |||
|
C047781
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
PRIMARY | |||
|
M6673
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
PRIMARY | Merck Index | ||
|
DB00555
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
PRIMARY | |||
|
LAMOTRIGINE
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
PRIMARY | |||
|
U3H27498KS
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
PRIMARY | |||
|
CHEMBL741
Created by
admin on Fri Jun 25 21:01:18 UTC 2021 , Edited by admin on Fri Jun 25 21:01:18 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
10% of dose
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
0-5% of dose
URINE
|
||
|
METABOLITE -> PARENT |
trace amount
|
||
|
METABOLITE -> PARENT |
80-90% of dose
MAJOR
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||